

COVID-19-Impfstoff von AstraZeneca: Vorübergehende Aussetzung!

Liebe Kolleginnen, liebe Kollegen,

Sie alle wissen wahrscheinlich bestens Bescheid über die *vorübergehende Aussetzung des Astra-Zeneca-Impfstoffs* durch den Bundesgesundheitsminister nach Empfehlung des Paul-Ehrlich-Instituts.

Die untenstehende Meldung der *Arzneimittelkommission der deutschen Ärzteschaft* führt über einen Hyperlink zur Meldung des PEI.

Was heute nicht klar genug herausgestellt wurde, ist der **Unterschied**

- zwischen der seit Tagen diskutierten Inzidenz von Thrombosen und Lungenembolien, die im Gegensatz zu vielen Sensationsnachrichten, *von allen Corona-Impfstoffen verursacht werden können*. Die Zahl liegt aber um ein Vielfaches unter der Thromboembolie-Häufigkeit bei Covid-19 Erkrankungen. [Die britischen Datenbanken zu Impfnebenwirkungen verzeichnen sowohl bei Biontech als auch bei AZD rund 50-60 Thrombosen und Lungenembolien pro 10 Millionen verimpften Dosen]

und

- dem Grund für die heutige Entscheidung: Dabei handelt es sich um ein überzufälliges Auftreten eines sehr seltenen sog. **Spontanen Heparin-induzierten Thrombopeniesyndroms**, das im Gegensatz zum Namen ohne externe Heparin-gabe auftritt und zu Thrombosen (hier Sinusvenenthrombosen) führen kann. Nach jetzigem Kenntnisstand sind (bei ca. 1,7 Millionen verimpften Dosen von AZD) 6 Frauen und ein Mann erkrankt. Drei dieser Menschen sind verstorben. Über ggf. vorliegende Risikofaktoren bei den Betroffenen liegen noch keine Informationen vor.

In der Literatur gibt es nur rel. wenige fundierte Arbeiten, die über diese seltene Erkrankung informieren. Ich habe Ihnen einen angemessen kurzen Artikel aus Blood (2014) angehängt, in dem Interessierte weitere Details finden können.

Und nun zur Meldung der AkdÄ:

Newsletter nicht lesbar? [Newsletter-Archiv online](#)



Arzneimittelkommission der deutschen Ärzteschaft
Wissenschaftlicher Fachausschuss der Bundesärztekammer

AkdÄ Drug Safety Mail | 2021–16

15.03.2021

Information des PEI zum COVID-19-Impfstoff von AstraZeneca: Vorübergehende Aussetzung

Nach Fallberichten schwerwiegender thrombotischer Ereignisse empfiehlt das Paul-Ehrlich-Institut (PEI) die vorübergehende Aussetzung der Impfungen mit dem COVID-19-Impfstoff von AstraZeneca. Dies betrifft sowohl Erst- als auch Folgeimpfungen.

Auffällig ist eine Häufung von Sinusvenenthrombosen in Verbindung mit einer Thrombozytopenie in zeitlichem Zusammenhang mit der Impfung. Die Daten werden derzeit durch die Europäische Arzneimittel-Agentur analysiert. Personen, die sich mehr als vier Tage nach der Impfung zunehmend unwohl fühlen (z. B. mit starken und anhaltenden Kopfschmerzen oder punktförmigen Hautblutungen) sollten sich unverzüglich in ärztliche Behandlung begeben.

☐ [Information des PEI vom 15.03.2021](#)

Bitte teilen Sie der AkdÄ beobachtete Nebenwirkungen und Medikationsfehler (auch Verdachtsfälle) mit. Die Formulare finden Sie auf der Webseite der AkdÄ.

Arzneimittelkommission der deutschen Ärzteschaft
Herbert-Lewin-Platz 1 • 10623 Berlin

Telefon: +49 30 400456-500
Telefax: +49 30 400456-555

newsletter@akdae.de
www.akdae.de

[Kontakt zur AkdÄ](#)
[Impressum](#)

[Arzneimittelsicherheit](#)
[Arzneimitteltherapie](#)
[Stellungnahmen](#)
[Die AkdÄ](#)
[Service](#)

Herzliche Grüße

Michael M. Kochen

Prof. Dr. med. Michael M. Kochen, MPH, FRCGP

Emeritus, Universitätsmedizin Göttingen | Institut f. Allgemeinmedizin, Universitätsklinikum Freiburg | Ordentliches Mitglied der Arzneimittelkommission der deutschen Ärzteschaft
Ludwigstr. 37, D-79104 Freiburg/Germany

THROMBOSIS AND HEMOSTASIS

Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder

Theodore E. Warkentin,¹ Paul A. Basciano,² Jared Knopman,³ and Richard A. Bernstein⁴¹Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; ²Department of Medicine, and ³Division of Interventional Neuroradiology, Department of Neurosurgery, Weill Cornell Medical Center, New York, NY; and ⁴Ken and Ruth Davee Department of Neurology and Clinical Neurological Sciences, Feinberg School of Medicine of Northwestern University, Chicago, IL

Key Points

- Two well-documented cases of a HIT-mimicking disorder without proximate heparin exposure (spontaneous HIT syndrome) are reported.
- The definition of spontaneous HIT syndrome should include strong serum-induced platelet activation at 0 IU/mL heparin (inhibited at 100 IU/mL).

The existence of spontaneous heparin-induced thrombocytopenia (HIT) syndrome (or autoimmune HIT), defined as a transient prothrombotic thrombocytopenic disorder without proximate heparin exposure serologically indistinguishable from HIT, is controversial. We describe 2 new cases presenting with thrombotic stroke/thrombocytopenia: one following shoulder hemi-arthroplasty (performed without heparin) and the other presenting to the emergency room without prior hospitalization, heparin exposure, or preceding infection. Both patients tested strongly positive for anti-platelet factor 4 (PF4)/heparin immunoglobulin (IgG) in 2 different immunoassays and in the platelet serotonin-release assay. Crucially, both patients' sera also caused strong (>80%) serotonin release in the absence of heparin, a serologic feature characteristic of delayed-onset HIT (ie, where heparin use precedes HIT but is not required for subsequent development or worsening of thrombocytopenia). We propose that a rigorous definition of spontaneous HIT syndrome should include otherwise unexplained thrombocytopenia/thrombosis without proximate heparin exposure and with anti-PF4/heparin IgG antibodies that cause strong in vitro platelet activation even in the absence of heparin. (*Blood*. 2014;123(23):3651-3654)

Introduction

Heparin-induced thrombocytopenia (HIT) is a transient, autoimmune-like, prothrombotic disorder caused by platelet-activating immunoglobulin (IgG) reactive against the self-protein, platelet factor 4 (PF4), bound to heparin.^{1,2} Rarely, a brief exposure to heparin triggers this adverse reaction beginning after stopping heparin (delayed-onset HIT); such patients' sera activate platelets strongly in vitro even in the absence of pharmacologic heparin.³ Previous reports⁴⁻⁷ suggest that an analogous syndrome can occur without preceding heparin exposure (spontaneous HIT syndrome or autoimmune HIT). We now report 2 new cases of spontaneous HIT syndrome, review the literature, and propose a clinical-pathological definition of this disorder including characteristic in vitro platelet activation features. We also suggest that the existence of spontaneous HIT syndrome following orthopedic surgery confounds interpretation of fondaparinux-associated HIT reported in that patient population.⁸⁻¹²

(measured prior to receiving heparin) was $65 \times 10^9/L$ (Figure 1A-B). There was no previous history of thrombocytopenia, hospitalization/surgery, previous heparin, infection, or other recent acute illness. MCA recanalization was initially achieved (Figure 1C) by mechanical thrombectomy (Solitaire stent-retriever) with unfractionated heparin (UFH; 1000 IU plus an unspecified amount as heparinized saline infusion), but 5 rapid episodes of rethrombosis (Figure 1D) required 5 further passes with the Solitaire device. Finally, patency (Figure 1E) was established with tissue plasminogen activator (15 mg) administered directly into the internal carotid artery terminus. A blood sample obtained prior to heparin administration tested strongly positive for HIT antibodies ("Results and discussion"). Treatment with aspirin, fondaparinux, and argatroban was administered, with subsequent warfarin. The platelet count remained low for 1 week (nadir, $27 \times 10^9/L$) and recovered by day 14.

Patient 2

A 54-year-old woman developed right leg swelling, left-upper extremity weakness/paresthesias, and thrombocytopenia ($61 \times 10^9/L$) 15 days after shoulder hemiarthroplasty; no intra-/postoperative heparin had been given, and no central/invasive lines were used. Brain magnetic resonance imaging demonstrated acute infarct in the left posterior inferior cerebellar artery territory; angiography showed nonvisualization of the left vertebral artery (V2 segment). Ultrasound venography showed right lower-extremity deep vein thrombosis. An echocardiographic saline bubble contrast study revealed no abnormalities. UFH treatment resulted in a further platelet count fall to

Study design

Patient 1

A 62-year-old man was admitted with left middle cerebral artery (MCA) thrombotic stroke and thrombocytopenia; his admission platelet count

Submitted January 15, 2014; accepted March 16, 2014. Prepublished online as *Blood* First Edition paper, March 27, 2014; DOI 10.1182/blood-2014-01-549741.

There is an Inside *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2014 by The American Society of Hematology




Figure 1. Patient 1: Clinical and radiological features. (A) Clinical course. (B) Thrombotic occlusion at internal carotid artery terminus. (C) Flow reestablished to MCA. (D) Reocclusion at origin of MCA (note: the unusual problem of 5 rapid rethromboses may have been related to heparin administration during the mechanical thrombectomies). (E) Flow reestablished to MCA and anterior cerebral artery (after infusion of tissue-plasminogen activator). No heparin exposure occurred as a result of the platelet transfusions (platelets were prepared using citrate anticoagulant). APTT, activated partial thromboplastin time; ASA, acetylsalicylic acid (aspirin); IU, international units; IV, intravenous; SC, subcutaneous; t-PA, tissue plasminogen activator; U, units; UFH, unfractionated heparin.

$37 \times 10^9/L$ (nadir). Subsequent treatment with argatroban followed by fondaparinux was associated with gradual platelet count recovery to $>150 \times 10^9/L$ by day 39.

Patient/control sera were tested for PF4-dependent antibodies using 3 enzyme immunoassays (EIAs): an in-house IgG-specific EIA¹³ and 2 commercial (Immucor GTI Diagnostics, Waukesha, WI)—one IgG-specific (Lifecodes PF4 IgG)¹³ the other a polyspecific EIA detecting IgG/IgA/IgM (Lifecodes PF4 Enhanced).¹⁴ We also performed the platelet serotonin release assay (SRA), as previously described.¹⁵ Both patients provided informed consent to report their cases. This study was conducted in accordance with the Declaration of Helsinki.

Results and discussion

Both patients' admission sera tested strongly positive for HIT antibodies by all 3 EIAs and in the SRA. Moreover, both patients' admission sera (obtained before heparin administration) caused strong platelet activation at 0.1 and 0.3 IU/mL UFH (100% serotonin release), as well as in the absence of heparin ($>80\%$ serotonin release), with no platelet activation at 100 IU/mL heparin (Table 1). Heparin-dependent platelet activation was confirmed using diluted patient sera (Table 1).

Similar serological features have been reported for patients with delayed-onset HIT,³ as well as in our initial report⁴ describing spontaneous HIT syndrome. Antibody reactivity declined markedly by 2 to 4 weeks (including disappearance of platelet-activating properties at 0 IU/mL heparin), in keeping with the usual transience of HIT antibodies,¹⁶ and paralleling both patients' platelet count recovery. Laboratory testing did not support a diagnosis of antiphospholipid syndrome in either patient (Table 1; both antiphospholipid syndrome and spontaneous HIT syndrome are potential explanations for thrombotic storm¹⁷).

These 2 cases further support spontaneous HIT syndrome as an unusual explanation for acute thrombosis and thrombocytopenia. Preceding orthopedic surgery is a possible trigger of these antibodies, as per patient 2 (present report) and as previously reported.⁵⁻⁷ Indeed, of the 7 previously reported cases of spontaneous HIT syndrome in which patients presented with thrombocytopenia and thrombosis in the absence of proximate heparin exposure, 5 occurred after orthopedic surgery (all with warfarin anticoagulation given after knee replacement surgery), whereas the remaining 2 cases occurred after infection. In patient 1 (present report), however, we could not identify a potentially causal proximate event. Including our 2 new cases (present report), plus 2 previously reported cases (patients

Table 1. Two patients with spontaneous HIT syndrome

Patient no. (age in years, gender)	Day of blood sample	SRA % serotonin release at different UFH concentrations (IU/mL)				PF4-dependent EIAs, absorbance, OD units (absorbance at high heparin)		
		0	0.1	0.3*	100	EIA-IgG, McMaster (negative < 0.45)	EIA-IgG, Immucor GTI (negative < 0.40)	EIA-IgG/A/M Immucor GTI (negative < 0.40)
1 (62, M)	Day 0 †	100‡	100‡	100	0	1.83 (0.29)	1.06 (0.07)	0.95 (0.130)
	Day 14	0	12	61	0	1.14 (0.30)	0.47 (ND)	0.54 (ND)
2 (54, F)	Day 0 †	81§	100§	100	0	2.89 (0.48)	2.87 (0.125)	2.80 (0.23)
	Day 28	2	81	100	0	2.58 (0.46)	2.98 (ND)	2.73 (ND)¶

Neither patient had laboratory evidence for microangiopathic hemolysis, vasculitis, or antiphospholipid antibodies (negative anticardiolipin and β_2 -glycoprotein-1 immunoassays, and normal dilute Russell viper venom time).

ND, not done.

*For both patients, % serotonin release was inhibited to 0% at 0.3 IU/mL UFH with Fc receptor-blocking monoclonal antibody (data not shown).

†Day 0 represents day of admission, with blood sample obtained before any administration of heparin.

‡Heparin-dependent platelet activation was evident using one-quarter diluted serum: 37% serotonin release at 0.1 IU/mL UFH vs 0% release at 0 IU/mL heparin (insufficient serum was available to test at one-half diluted serum).

§Heparin-dependent platelet activation was evident using one-eighth diluted serum (94% serotonin release at 0.1 IU/mL UFH vs 18% serotonin release at 0 IU/mL heparin) and using one-sixteenth diluted serum (85% serotonin release at 0.1 IU/mL UFH vs 3% release at 0 IU/mL UFH).

¶For patient 2, subsequent results in the EIA-IgG/A/M (Immucor GTI) were as follows: 0.95 (day 100) and 0.25 (day 240).

1 and 2 in our initial report⁴), there have now been 4 patients with putative spontaneous HIT syndrome investigated in the McMaster Platelet Immunology Laboratory. All 4 sera yielded substantial platelet activation (mean, 76%) in the absence of pharmacologic heparin. This is a crucial observation, as it may explain how anti-PF4/heparin antibodies can induce intravascular platelet activation at a time when no heparin is being administered.

Spontaneous HIT syndrome should not be confused with a related clinical picture resembling rapid-onset HIT triggered by therapeutic dose heparin administration in which, however, no preceding heparin exposure can be identified, yet the patients have circulating anti-PF4/heparin antibodies. This situation has been documented in 2 patients^{4,18} (without previous heparin exposure) who initially presented with normal platelet counts but then developed acute thrombocytopenia on receiving a therapeutic dose of low-molecular-weight heparin⁴ or UFH.¹⁸ Importantly, neither serum caused platelet activation at 0 IU/mL heparin, consistent with serum-induced platelet activation that occurs in the absence of heparin (ie, at buffer control), which is important in explaining spontaneous HIT syndrome that presents with thrombocytopenia.

We believe our observations could also have relevance to the understanding of the pathogenesis of fondaparinux-associated HIT. To date, 6 relatively well-documented cases of HIT following fondaparinux thromboprophylaxis have been reported,⁸⁻¹² without any apparent preceding heparin exposure. Notably, 5 of the 6 patients had preceding orthopedic surgery (all but 1 post-knee replacement), raising the possibility that fondaparinux could be an innocent bystander, ie, the orthopedic surgery itself could have been the trigger of the subsequent anti-PF4/heparin immune response. Indeed, only minor enhancement of platelet activation *in vitro* in the presence of fondaparinux has been observed in these patients.^{10,12} It is plausible that nonheparin triggers of the anti-PF4/heparin immune response, such as glycosaminoglycans released during orthopedic surgery, or bacterial antigens in the case of preceding infection, could account for these unusual clinical observations (bacterial cell walls¹⁹ and RNA/DNA nucleotides²⁰ bind to PF4, recapitulating HIT antigens, and murine¹⁹ and human bacterial infection²¹ are associated with anti-PF4/heparin antibody formation).

We propose that a definitive diagnosis of spontaneous HIT syndrome should be based on the following criteria: thrombocytopenia (without alternate explanation), thrombosis, lack of proximate heparin exposure, strong positive PF4-dependent EIAs (≥ 2 different assays), a strong positive platelet activation assay ($>80\%$ peak serotonin release) featuring strong heparin-independent platelet

activation ($>50\%$ serotonin release at 0 IU/mL heparin), as well as heparin-dependent platelet activation (evident on serum dilution), and exhibiting also the other characteristic features of HIT sera (inhibition at 100 IU/mL heparin and with Fc receptor-blocking monoclonal antibody). Although fulfilling all of these aforementioned criteria will require serum referral for specialized laboratory investigations (namely, the SRA or another functional assay such as the heparin-induced platelet activation test,²² performed using neat and diluted serum and also including buffer control), initial treatment of presumptive spontaneous HIT syndrome should not be delayed; moreover, our proposed rigorous definition will avoid potential overdiagnosis that could occur if a positive EIA alone was used to detect anti-PF4/heparin antibodies in a patient who presented with otherwise unexplained thrombocytopenia.

Acknowledgments

The authors thank Jo-Ann I. Sheppard for technical assistance and for help in the preparation of the figure.

This work was supported by grant T6950 (T.E.W.) from the Heart and Stroke Foundation of Ontario (Toronto, ON, Canada).

Authorship

Contribution: T.E.W. designed and supervised the experiments, analyzed the data, and interpreted the results; P.A.B., J.K., and R.A.B. identified the 2 patients, referred acute and follow-up patient sera to the McMaster Platelet Immunology Laboratory, and obtained the clinical data; and T.E.W., P.A.B., J.K., and R.A.B. reviewed and approved the final version of the manuscript.

Conflict-of-interest disclosure: T.E.W. has received lecture honoraria from Pfizer Canada and Instrumentation Laboratory and research funding from GlaxoSmithKline and Immucor GTI Diagnostics and has provided expert witness testimony relating to HIT. The remaining authors declare no competing financial interests.

Correspondence: Theodore E. Warkentin, Hamilton Regional, Laboratory Medicine Program, Rm 1-270B, Hamilton Health, Sciences (General Site), 237 Barton St E, Hamilton, ON, Canada L8L2X2; e-mail: twarken@mcmaster.ca.

References

- Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. *N Engl J Med*. 2013;368(8):737-744.
- Bakchoul T, Greinacher A. Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. *Ther Adv Hematol*. 2012;3(4):237-251.
- Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. *Ann Intern Med*. 2001;135(7):502-506.
- Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. *Am J Med*. 2008;121(7):632-636.
- Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT? *J Thromb Haemost*. 2008;6(9):1598-1600.
- Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery 'spontaneous' HIT. *J Thromb Haemost*. 2009;7(3):499-501.
- Ketha S, Smithedajkul P, Vella A, Pruthi R, Wysokinski W, McBane R. Adrenal haemorrhage due to heparin-induced thrombocytopenia. *Thromb Haemost*. 2013;109(4):669-675.
- Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. *N Engl J Med*. 2007;356(25):2653-2655, discussion 2653-2655.
- Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). *Thromb Haemost*. 2008;99(4):779-781.
- Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. *Thromb Haemost*. 2010;104(5):1071-1072.
- Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. *Proc (Bayl Univ Med Cent)*. 2012;25(1):13-15.
- Warkentin TE, Chakraborty AK, Sheppard JA, Griffin DK. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. *Thromb Haemost*. 2012;108(2):394-396.
- Warkentin TE, Sheppard JI, Moore JC, Kelton JG. The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. *J Thromb Haemost*. 2010;8(1):216-218.
- Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. *J Lab Clin Med*. 2001;138(1):22-31.
- Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. *J Lab Clin Med*. 1992;120(3):371-379.
- Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med*. 2001;344(17):1286-1292.
- Ortel TL, Kitchens CS, Erkan D, et al. Clinical causes and treatment of the thrombotic storm. *Expert Rev Hematol*. 2012;5(6):653-659.
- Perrin J, Barraud D, Toussaint-Hacquard M, Bollaert PE, Lecompte T. Rapid onset heparin-induced thrombocytopenia (HIT) without history of heparin exposure: a new case of so-called 'spontaneous' HIT. *Thromb Haemost*. 2012;107(4):795-797.
- Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. *Blood*. 2011;117(4):1370-1378.
- Jaax ME, Krauel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. *Blood*. 2013;122(2):272-281.
- Pongas G, Dasgupta SK, Thiagarajan P. Antiplatelet factor 4/heparin antibodies in patients with gram negative bacteremia. *Thromb Res*. 2013;132(2):217-220.
- Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. *Thromb Haemost*. 1991;66(6):734-736.